Cognition Therapeutics, Inc. (CGTX) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
7/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinCGTX / S&P 51.32% / 15.20% |
LoseCGTX / S&P CGTX unavailable / 15.00% |
LoseCGTX / S&P -74.63% / 50.40% |
| 2026-Q10/3 |
LoseCGTX / S&P -43.70% / -4.33% |
LoseCGTX / S&P CGTX unavailable / 11.30% |
LoseCGTX / S&P -67.57% / 27.70% |
| 2025-Q40/3 |
LoseCGTX / S&P 0.00% / 2.65% |
LoseCGTX / S&P CGTX unavailable / 9.00% |
LoseCGTX / S&P -62.07% / 13.40% |
| 2025-Q31/3 |
WinCGTX / S&P 335.48% / 8.12% |
LoseCGTX / S&P CGTX unavailable / 4.61% |
LoseCGTX / S&P -50.52% / 13.45% |
| 2025-Q20/3 |
LoseCGTX / S&P -26.37% / 10.94% |
LoseCGTX / S&P CGTX unavailable / 4.83% |
LoseCGTX / S&P -28.72% / 10.63% |
| 2025-Q10/3 |
LoseCGTX / S&P -39.94% / -4.27% |
LoseCGTX / S&P CGTX unavailable / 4.98% |
LoseCGTX / S&P -19.57% / 10.57% |
| 2024-Q41/3 |
WinCGTX / S&P 49.47% / 2.41% |
LoseCGTX / S&P CGTX unavailable / 5.25% |
LoseCGTX / S&P 1.16% / 6.15% |
| 2024-Q31/3 |
LoseCGTX / S&P -71.75% / 5.89% |
LoseCGTX / S&P CGTX unavailable / 5.89% |
WinCGTX / S&P 22.78% / 6.11% |
| 2024-Q21/3 |
LoseCGTX / S&P -8.79% / 4.28% |
LoseCGTX / S&P CGTX unavailable / 5.38% |
WinCGTX / S&P 9.30% / 5.12% |
| 2024-Q10/3 |
LoseCGTX / S&P -1.62% / 10.56% |
LoseCGTX / S&P CGTX unavailable / 5.71% |
LoseCGTX / S&P -3.16% / 5.59% |
| 2023-Q41/3 |
WinCGTX / S&P 28.47% / 11.69% |
LoseCGTX / S&P CGTX unavailable / 6.81% |
LoseCGTX / S&P -5.49% / 7.78% |
| 2023-Q30/3 |
LoseCGTX / S&P -21.31% / -3.27% |
LoseCGTX / S&P CGTX unavailable / 7.52% |
LoseCGTX / S&P -107.16% / -5.03% |
| 2023-Q20/3 |
LoseCGTX / S&P -7.58% / 8.74% |
LoseCGTX / S&P CGTX unavailable / 9.50% |
LoseCGTX / S&P -126.88% / -8.57% |
| 2023-Q10/3 |
LoseCGTX / S&P -5.71% / 7.50% |
LoseCGTX / S&P CGTX unavailable / 10.77% |
LoseCGTX / S&P -28.03% / -15.69% |
| 2022-Q41/3 |
WinCGTX / S&P 10.53% / 7.56% |
LoseCGTX / S&P CGTX unavailable / 11.88% |
LoseCGTX / S&P -67.38% / -17.99% |
| 2022-Q30/3 |
LoseCGTX / S&P -9.95% / -4.88% |
LoseCGTX / S&P CGTX unavailable / 13.47% |
LoseCGTX / S&P -155.29% / -1.41% |
| 2022-Q20/3 |
LoseCGTX / S&P -23.27% / -16.10% |
LoseCGTX / S&P CGTX unavailable / 13.71% |
LoseCGTX / S&P -118.67% / 11.04% |
| 2022-Q10/3 |
LoseCGTX / S&P -56.49% / -4.60% |
LoseCGTX / S&P CGTX unavailable / 15.97% |
LoseCGTX / S&P CGTX unavailable / 42.23% |
| 2021-Q40/3 |
LoseCGTX / S&P CGTX unavailable / 11.03% |
LoseCGTX / S&P CGTX unavailable / 15.00% |
LoseCGTX / S&P CGTX unavailable / 96.40% |
| 2021-Q30/3 |
LoseCGTX / S&P CGTX unavailable / 0.58% |
LoseCGTX / S&P CGTX unavailable / 10.77% |
LoseCGTX / S&P CGTX unavailable / 69.42% |
| 2021-Q20/3 |
LoseCGTX / S&P CGTX unavailable / 8.55% |
LoseCGTX / S&P CGTX unavailable / 6.58% |
LoseCGTX / S&P CGTX unavailable / 51.81% |
| 2021-Q10/3 |
LoseCGTX / S&P CGTX unavailable / 6.17% |
LoseCGTX / S&P CGTX unavailable / -1.06% |
LoseCGTX / S&P CGTX unavailable / 7.39% |
| 2020-Q40/3 |
LoseCGTX / S&P CGTX unavailable / 12.15% |
LoseCGTX / S&P CGTX unavailable / -3.72% |
LoseCGTX / S&P CGTX unavailable / -33.42% |
| 2020-Q30/3 |
LoseCGTX / S&P CGTX unavailable / 8.93% |
LoseCGTX / S&P CGTX unavailable / -2.04% |
LoseCGTX / S&P CGTX unavailable / -27.10% |
| 2020-Q20/3 |
LoseCGTX / S&P CGTX unavailable / 20.54% |
LoseCGTX / S&P CGTX unavailable / -0.46% |
LoseCGTX / S&P CGTX unavailable / -27.11% |
| 2020-Q10/3 |
LoseCGTX / S&P CGTX unavailable / -19.60% |
LoseCGTX / S&P CGTX unavailable / 3.47% |
LoseCGTX / S&P CGTX unavailable / -14.75% |
| 2019-Q40/3 |
LoseCGTX / S&P CGTX unavailable / 9.07% |
LoseCGTX / S&P CGTX unavailable / 5.36% |
LoseCGTX / S&P CGTX unavailable / 2.99% |
| 2019-Q30/3 |
LoseCGTX / S&P CGTX unavailable / 1.70% |
LoseCGTX / S&P CGTX unavailable / 5.02% |
LoseCGTX / S&P CGTX unavailable / 0.21% |
| 2019-Q20/3 |
LoseCGTX / S&P CGTX unavailable / 4.30% |
LoseCGTX / S&P CGTX unavailable / 6.64% |
LoseCGTX / S&P CGTX unavailable / 8.65% |
| 2019-Q10/3 |
LoseCGTX / S&P CGTX unavailable / 13.65% |
LoseCGTX / S&P CGTX unavailable / 8.12% |
LoseCGTX / S&P CGTX unavailable / 14.29% |
| 2018-Q40/3 |
LoseCGTX / S&P CGTX unavailable / -13.52% |
LoseCGTX / S&P CGTX unavailable / 9.05% |
LoseCGTX / S&P CGTX unavailable / 18.23% |
| 2018-Q30/3 |
LoseCGTX / S&P CGTX unavailable / 7.71% |
LoseCGTX / S&P CGTX unavailable / 10.21% |
LoseCGTX / S&P CGTX unavailable / 19.06% |
| 2018-Q20/3 |
LoseCGTX / S&P CGTX unavailable / 3.43% |
LoseCGTX / S&P CGTX unavailable / 9.03% |
LoseCGTX / S&P CGTX unavailable / 14.46% |
| 2018-Q10/3 |
LoseCGTX / S&P CGTX unavailable / -0.76% |
LoseCGTX / S&P CGTX unavailable / 7.68% |
LoseCGTX / S&P CGTX unavailable / 12.46% |
| 2017-Q40/3 |
LoseCGTX / S&P CGTX unavailable / 6.64% |
LoseCGTX / S&P CGTX unavailable / 7.03% |
LoseCGTX / S&P CGTX unavailable / 13.82% |
| 2017-Q30/3 |
LoseCGTX / S&P CGTX unavailable / 4.48% |
LoseCGTX / S&P CGTX unavailable / 5.68% |
LoseCGTX / S&P CGTX unavailable / 17.57% |
| 2017-Q20/3 |
LoseCGTX / S&P CGTX unavailable / 3.09% |
LoseCGTX / S&P CGTX unavailable / 4.83% |
LoseCGTX / S&P CGTX unavailable / 17.74% |
| 2017-Q10/3 |
LoseCGTX / S&P CGTX unavailable / 6.07% |
LoseCGTX / S&P CGTX unavailable / 3.67% |
LoseCGTX / S&P CGTX unavailable / 13.32% |
| 2016-Q40/3 |
LoseCGTX / S&P CGTX unavailable / 3.82% |
LoseCGTX / S&P CGTX unavailable / 2.09% |
LoseCGTX / S&P CGTX unavailable / 7.05% |
| 2016-Q30/3 |
LoseCGTX / S&P CGTX unavailable / 3.85% |
LoseCGTX / S&P CGTX unavailable / 0.20% |
LoseCGTX / S&P CGTX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CGTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -56.38% | 20.78% |
| Annualized return | -56.38% | 20.78% |
5Y · 2021-10-08 to 2026-08-27
| Metric | CGTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -91.70% | 83.14% |
| Annualized return | -39.21% | 12.86% |
10Y · 2021-10-08 to 2026-08-27
| Metric | CGTX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -91.70% | 319.30% |
| Annualized return | -22.03% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |